secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001213900-26-035971
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara reports 68% six-month CR rate in TARA-002 trial; triggers warrant exercise period
--------------------------------------------------------------------------------

- Six-month complete response (CR) rate of 68.0% in 25 BCG-unresponsive NMIBC patients in Phase 2 ADVANCED-2 trial.
- CR rate is consistent with the 68.2% announced on February 24, 2026, and meaningfully above 41.9% threshold.
- Condition met for fixing termination date of April 2024 common stock warrants; exercisable at $5.25 through June 29, 2026.
- Results from open-label trial; further updates may be required for regulatory discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026035971/0001213900-26-035971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026035971/ea0283949-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-035971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer